Key Points {#d30e209}
==========

Age, sex, and race appear to have no clinically significant impact on the pharmacokinetics of azilsartan.No adjustments in azilsartan medoxomil dosage are required on the basis of age, sex, or race.

Introduction {#Sec1}
============

The use of drugs acting on the renin-angiotensin system (RAS), principally angiotensin converting enzyme inhibitors and angiotensin II receptor blockers (ARBs), has become established as an important component in the contemporary management of patients with hypertension \[[@CR1]\]. The latest JNC8 Guidelines recommend RAS inhibitors (alone or in combination with other drugs) as the first-line therapy treatment for patients with chronic kidney disease (CKD), with or without diabetes mellitus and for all ages and races \[[@CR1]\]. These agents are also one of the recommended first-line agents for those without CKD, especially in non-black patients \[[@CR1]\]. As second-line agents, RAS inhibitors are one of the recommended components of combination therapy available to patients irrespective of age, sex, or race \[[@CR1]\].

Azilsartan medoxomil (AZL-M) is a potent ARB approved for the treatment of hypertension at a dose of 20--80 mg once daily, alone or in combination with other antihypertensive agents \[[@CR2]--[@CR5]\]. After oral dosing, AZL-M (a pro-drug) is rapidly hydrolyzed during absorption in the gut and/or gut wall to form its active moiety, azilsartan (AZL) \[[@CR2], [@CR5]\]. Unchanged AZL-M is not detected in blood at any time. Based on previous pharmacokinetic analyses, peak plasma concentrations of AZL are reached within 1.5--3 h after oral dosing, elimination half-life is approximately 11 h, and renal clearance is approximately 2.3 mL/min \[[@CR2], [@CR5]\]. Assuming total conversion to AZL, the apparent oral clearance of AZL-M after non-compartmental analysis is approximately 1.5 L/h \[[@CR6]\]. Systemic exposure of AZL with the capsule formulation of AZL-M (as used in the initial clinical development phase and in the current study) was shown to be higher when the capsules were administered with food. This food-effect response was minimized with the commercial tablet formulation.

Both renal and hepatic metabolism contribute to the elimination of AZL, although neither mild-to-severe renal impairment nor mild-to-moderate hepatic impairment has any clinically relevant impact on AZL exposure \[[@CR2], [@CR5], [@CR7], [@CR8]\]. Systemic exposure of the main metabolite of AZL (M-II; formed by *O*-dealkylation via the cytochrome P450 2C9 isoform) is also unchanged with hepatic impairment, but is increased in patients with renal impairment; however, this increase has no clinical relevance because M-II is not pharmacologically active \[[@CR2], [@CR5], [@CR7], [@CR8]\]. Similarly, the minor metabolite M-I (formed by decarboxylation) is not pharmacologically relevant \[[@CR2], [@CR5]\].

The possibility of alterations in AZL pharmacokinetics in the elderly is a particularly important consideration because of the potential for age-related impairments in physiologic processes and the resultant decline in drug metabolism and excretion \[[@CR9], [@CR10]\]. In addition, potential pharmacokinetic differences according to sex and/or race remain a key consideration with all pharmacologic agents. If clinically relevant differences in drug exposure are present, dose adjustments or altered dosing schedules may be required in specific patient populations to maximize efficacy or minimize the risk of adverse effects.

Because hypertension can affect any individual, regardless of age, sex, or race, it is important to establish the pharmacokinetic and tolerability/safety profile of AZL within these populations. The current study evaluated the possible effects of age, sex, and race on AZL pharmacokinetics and AZL safety/tolerability after single and multiple (five consecutive) daily doses of AZL-M 60 mg in healthy adult subjects.

Methods {#Sec2}
=======

This was a phase I, single-center, single-blind, randomized, parallel-group, single- and multiple-dose, placebo-controlled study. The placebo-controlled component was for the assessment of safety only. The study was performed at Arkansas Research Medical Testing, Little Rock, AR, USA, where it was approved by the Institutional Review Board for Arkansas Research Medical Testing, Little Rock, AR, USA and undertaken in accordance with the Declaration of Helsinki. Written informed consent was obtained directly from all participants prior to entry into the study and prior to any study procedures.

Study Participants {#Sec3}
------------------

The study population consisted of 61 healthy, non-hypertensive black or white men or women aged 18--45 years ("young") or 65--85 years ("elderly"), with a body mass index (BMI) of 18--33 kg/m^2^ and minimum body weight of 50 kg. Exclusion criteria included: (1) history of drug/alcohol abuse; (2) history or clinical manifestations of significant metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urologic, immunologic, or psychiatric disorders (unless approved on a case-by-case basis); (3) abdominal surgery or thoracic or nonperipheral vascular surgery in the previous 6 months; (4) systolic blood pressure \>140 or \<110 mmHg, or a diastolic blood pressure \>90 or \<70 mmHg; (5) history or presence of an abnormal, clinically significant 12-lead ECG result; (6) pregnancy/lactation; (7) hemoglobin \<12 g/dL; (8) alanine transaminase level \>1.5 × upper limit of normal, active liver disease, or jaundice; (9) blood donation or acute blood loss \>500 mL in the previous 30 days; (10) history of cancer (except basal cell or stage 1 squamous cell carcinoma of the skin) that had not been in remission for the previous 5 years; and (11) tobacco or nicotine product use in the previous 30 days.

The following medications/food products were prohibited for the duration of the subject's participation in the study and for varying time periods prior to study entry: (1) prescription medications (except those approved on a case-by-case basis) and neutraceuticals (28 days prior to study entry); (2) over-the-counter medications (except those approved on a case-by-case basis) and vitamin supplements (14 days prior to study entry); and (3) alcohol- and caffeine-containing products, foods, or beverages containing Seville (sour) orange- and grapefruit-containing products (72 h prior to study entry).

Subjects were stratified according to age (young \[Y\]or elderly \[E\]), sex (male \[M\] or female \[F\]), and race (black \[B\] or white \[W\]) into eight treatment groups (YFB, EFB, YMB, EMB, YFW, EFW, YMW, EMW). Each group consisted of eight subjects---six randomized to receive AZL-M 60 mg and two randomized to receive placebo. Because of the difficulty in enrollments, the EFB group was an exception (*n* = 5), with no subjects receiving placebo. Following screening (Days −28 to −2), subjects were admitted to the clinic on Day −1 and confined to the clinic for a total of 9 nights until Day 9.

Treatment Allocation {#Sec4}
--------------------

Randomly allocated study treatment (AZL-M 60 mg \[3 × 20 mg oral capsules\] or matching placebo) was administered once per day in the morning as a single dose on Day 1 and consecutive single doses on Days 4--8, inclusive. Treatment was administered immediately following consumption of a standardized breakfast containing approximately 600--800 kcal and approximately 30 % fat. The 60-mg dose of the AZL-M capsule was chosen for the current study as it provided a significant decrease in blood pressure, while being safe and well tolerated, in early clinical studies where AZL-M was administered without regard to meals (US FDA, 2011).

Bioanalytical Methods {#Sec5}
---------------------

Blood samples were obtained at time points up to 72 h post-dose after the single dose on Day 1, before dosing on Days 6, 7, and 8, and up to 24 h post-dose after the last dose on Day 8 to determine the concentrations of AZL. All blood samples were collected into chilled 6-mL tubes containing potassium ethylene diamine tetra-acetic acid and centrifuged, and the plasma was then removed. Samples were stored at approximately −70 °C or lower.

The AZL concentrations in plasma samples were determined using a validated liquid chromatography-tandem mass spectrometry assay at Covance Laboratories, Madison, WI, USA. The samples were acidified and the internal standard was added. AZL and the internal standard were then extracted using OASIS^®^ HLB, 96-well solid-phase extraction plates (Waters, Milford, MA, USA). Liquid chromatography separation was obtained using an Xterra^®^ RP18 column (Waters; 250 × 2.1 mm, 5 µm). The mobile phase consisted of an acetonitrile:water:acetic acid gradient (60:40:0.05, v:v:v)/acetonitrile and was pumped through the column at a flow rate of 0.2 mL/min. For detection, an API 3000 mass spectrometer (AB Sciex, Framingham, MA, USA) with positive ion electrospray in multiple-reaction monitoring mode was used. The LC-MS/MS assay range and precision for the quality control samples in this study were 1.00--2500 ng/mL and 3.6--8.0 %, respectively.

Pharmacokinetic and Safety Assessments {#Sec6}
--------------------------------------

Pharmacokinetic variables derived from AZL concentrations in plasma were calculated, including AUC~0--∞~ (area under the plasma concentration-time curve from time 0 h to infinity, single dose only, Day 1); AUC~0--24~ (area under the plasma concentration-time curve from time 0 to 24 h post dose \[one dose interval\], after multiple doses only, Day 8); *C*~max~ (maximum observed drug concentration in plasma); *t*~max~ (time to reach *C*~max~); and *t*~½~ (terminal half-life, single dose only). Pre-dose trough concentration (*C*~min~) was also assessed on Days 6--8. Pharmacokinetic parameters were derived using noncompartmental methods with WinNonlin^®^ Professional Version 4.10 (Pharsight Corp., Mountain View, CA, USA).

Placebo subjects were assessed for safety/tolerability only. Safety and tolerability parameters included adverse events, clinical laboratory tests (hematology and serum chemistry), vital signs, 12-lead electrocardiogram, and physical examination findings.

Statistical Analysis {#Sec7}
--------------------

All data analyses were performed using Statistical Analysis System (SAS^®^, Version 9.1, SAS Institute, Cary, NC, USA). An alpha of 0.05 was used for any hypothesis tests performed. Descriptive statistics were used to summarize the pharmacokinetic parameters according to age, sex, and race. An analysis of covariance (ANCOVA) was performed (with fixed effects for age, sex, and race, and body weight as a covariate) on the natural logarithms of the pharmacokinetic variables AUC~0--∞~, AUC~0--24~, and *C*~max~. Point estimates for comparing groups (elderly vs. young, female vs. male, white vs. black) were calculated and presented as ratios; these were obtained by exponentiating estimates of the difference in between-group least-squares means on the log-transformed parameters obtained within the framework of the ANCOVA model. Confidence intervals (CIs) for these estimates were similarly obtained by exponentiating the endpoints of 90 % CIs for the between-group differences of the log-transformed parameters.

To assess linear kinetics of AZL, an analysis of variance (ANOVA) with fixed effects for age, race, sex, day, interaction terms age-by-race, age-by-sex, race-by-sex, and age-by-race-by-sex, and subject nested within age-by-race-by-sex as random effect was performed on the natural logarithms of AUC~0--∞~ for the single dose (Day 1) and AUC~0--24~ for the multiple dose (Day 8) for AZL. A 90 % CI for the ratio of the least squares means of the multiple-dose AUC~0--24~ relative to the single-dose AUC~0--∞~ was derived within the framework of ANOVA.

The natural logarithms of pre-dose concentrations on Days 6, 7, and 8 were analyzed to assess the achievement of steady state. An ANOVA with the same interaction terms listed above was performed. Within the model, a pairwise *t* test was used to assess the achievement of steady state by comparing the pre-dose concentration between study days.

Results {#Sec8}
=======

Subject Characteristics {#Sec9}
-----------------------

Demographic and baseline characteristics for the subject population are summarized in Table [1](#Tab1){ref-type="table"}. Mean age was approximately 31 years for "young" subjects and 70 years for "elderly" subjects, and mean BMI was approximately 27 kg/m^2^. The AZL-M and placebo groups had similar demographic characteristics. All subjects completed the study.Table 1Demographic and baseline characteristics stratified by age, sex, and raceDemographic variableAzilsartan medoxomilPlaceboAzilsartan medoxomilPlaceboAgeElderlyYoung *N*236248 Age, years (mean ± SD)68.7 (4.8)73.0 (5.8)31.4 (8.6)30.0 (7.0) Sex, female/male (*n*)11/122/412/124/4 Race, white/black (*n*)12/114/212/124/4 BMI, kg/m^2^ (mean ± SD)28.2 (3.3)26.7 (3.5)25.8 (3.8)27.0 (4.2) Body weight, kg (mean ± SD)81.2 (12.6)81.0 (18.9)75.9 (10.4)81.4 (15.5)SexFemaleMale *N*236248 Age, years (mean ± SD)49.0 (19.7)47.2 (21.5)50.2 (20.9)49.4 (25.4) Race, white/black (*n*)12/114/212/124/4 BMI, kg/m^2^ (mean ± SD)27.7 (4.1)26.4 (4.5)26.4 (3.3)27.3 (3.4) Body weight, kg (mean ± SD)74.5 (9.8)71.5 (12.0)82.4 (12.2)88.6 (15.8)RaceWhiteBlack *N*248236 Age, years (mean ± SD)49.1 (23.0)54.5 (24.0)50.2 (17.1)40.3 (20.7) Sex, female/male (*n*)12/124/411/122/4 BMI, kg/m^2^ (mean ± SD)27.2 (3.5)27.5 (2.2)26.8 (4.0)26.1 (5.4) Body weight, kg (mean ± SD)78.8 (12.9)83.7 (11.8)78.2 (10.5)77.9 (21.9)*BMI* body mass index, *Black* Black or African American, *Elderly* age 65--85 years, *Young* age 18--45 years, *SD* standard deviation

Azilsartan Pharmacokinetics {#Sec10}
---------------------------

The AZL concentration-time profiles after a single dose (Day 1) and after multiple dosing (Day 8) of AZL-M according to age, sex, and race are shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, and pharmacokinetic parameter estimates are shown in Table [2](#Tab2){ref-type="table"}. Elderly subjects had a higher total AZL exposure (AUC) after both a single dose (ratio 1.36, 90 % CI 1.05, 1.77) and after multiple dosing (ratio 1.26, 90 % CI 1.01, 1.57) compared with young subjects (Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). Elderly subjects also had higher peak AZL exposure (*C*~max~) after both a single dose (ratio 1.37, 90 % CI 1.02, 1.86) and after multiple dosing (ratio 1.15, 90 % CI 0.89, 1.49) compared with young subjects (Table [3](#Tab3){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). There were no clinically relevant differences for female vs. male subjects or black vs. white subjects in terms of total or peak AZL exposure after either a single dose or after multiple dosing (Table [3](#Tab3){ref-type="table"}; Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). No notable differences in time to peak exposure (*t*~max~) were evident according to age, sex, and race (Table [2](#Tab2){ref-type="table"}).Fig. 1Azilsartan concentration--time profiles after a single dose (Day 1) of azilsartan medoxomil according to age (*top*), sex (*middle*), and race (*bottom*). All data are mean ± standard error of the meanFig. 2Azilsartan concentration--time profiles after multiple dosing (Day 8) of azilsartan medoxomil according to age (*top*), sex (*middle*), and race (*bottom*). All data are mean ± standard error of the meanTable 2Descriptive statistics for azilsartan plasma pharmacokinetic parameters according to age, sex, and raceParameterArithmetic mean ± SD or median \[min, max\]AgeElderly (*n* = 23)Young (*n* = 24) Single dose (Day 1)  AUC~0--∞~ (ng·h/mL)26739 ± 9027^a^21424 ± 7221^b^  *C* ~max~ (ng/mL)3031 ± 11102520 ± 1206  *t* ~max~ (h)6.0 \[3.0, 12.0\]5.0 \[3.0, 24.0\]  *t* ~½~ (h)12.17 ± 1.94^a^10.64 ± 1.47^b^Multiple dose (Day 8)  AUC~0--24h~ (ng·h/mL)25445 ± 956321502 ± 7693  *C* ~max~ (ng/mL)3253 ± 14353049 ± 1319  *t* ~max~ (h)4.0 \[1.0, 8.0\]4.0 \[2.0, 8.0\]SexFemale (*n* = 23)Male (*n* = 24) Single dose (Day 1)  AUC~0--∞~ (ng·h/mL)25773 ± 9525^a^22348 ± 7195^b^  *C* ~max~ (ng/mL)3023 ± 13822527 ± 901  *t* ~max~ (h)6.0 \[3.0,12.0\]4.0 \[3.0, 24.0\]  *t* ~½~ (h)11.40 ± 1.37^a^11.38 ± 2.27^b^ Multiple dose (Day 8)  AUC~0--24h~ (ng·h/mL)25328 ± 931321614 ± 8037  *C* ~max~ (ng/mL)3536 ± 14822778 ± 1156  *t* ~max~ (h)4.0 \[1.0, 8.0\]4.0 \[2.0, 8.0\]RaceWhite (*n* = 24)Black (*n* = 23) Single dose (Day 1)  AUC~0--∞~ (ng·h/mL)25930 ± 8827^b^22028 ± 7840^a^  *C* ~max~ (ng/mL)2816 ± 12282721 ± 1146  *t* ~max~ (h)6.0 \[3.0, 24.0\]6.0 \[3.0, 12.0\]  *t* ~½~ (h)11.67 ± 2.09^b^11.09 ± 1.58^a^ Multiple dose (Day 8)  AUC~0--24h~ (ng·h/mL)24320 ± 875222505 ± 8932  *C* ~max~ (ng/mL)3365 ± 10532924 ± 1624  *t* ~max~ (h)4.0 \[2.0, 8.0\]4.0 \[1.0, 8.0\]*t* ~*½*~ terminal half-life, *AUC* ~*0--24h*~ area under the plasma concentration-time curve from time 0 to 24 h post dose, *AUC* ~*0--∞*~ area under the plasma concentration-time curve from time 0 h to infinity~,~ *C* ~*max*~ maximum observed drug concentration in plasma, *t* ~*max*~ time to reach C~max,~ *SD* standard deviation, *min* minimum, *max* maximum^a^ *n* = 22^b^ *n* = 23Table 3Statistical analysis of azilsartan plasma pharmacokinetic parameters according to age, sex, and raceParameterLS meanLS meanRatio \[90 % CI\]AgeElderly (*n* = 23)Young (*n* = 24)Elderly/young Single dose (Day 1)  AUC~0--∞~ (ng·h/mL)26,003^a^19,062^b^1.36 \[1.05, 1.77\]  *C* ~max~ (ng/mL)287620931.37 \[1.02, 1.86\] Multiple dose (Day 8)  AUC~0--24~ (ng·h/mL)24,37519,3841.26 \[1.01, 1.57\]  *C* ~max~ (ng/mL)303626381.15 \[0.89, 1.49\]SexFemale (*n* = 23)Male (*n* = 24)Female/male Single dose (Day 1)  AUC~0--∞~ (ng·h/mL)22,577^a^21,955^b^1.03 \[0.78, 1.36\]  *C* ~max~ (ng/mL)247824301.02 \[0.75, 1.39\] Multiple dose (Day 8)  AUC~0--24~ (ng·h/mL)22,56520,9381.08 \[0.86, 1.36\]  *C* ~max~ (ng/mL)304926271.16 \[0.89, 1.52\]RaceWhite (*n* = 24)Black (*n* = 23)White/black Single dose (Day 1)  AUC~0--∞~ (ng·h/mL)24,599^b^20,150^a^1.22 \[0.95, 1.58\]  *C* ~max~ (ng/mL)254723641.08 \[0.81, 1.44\] Multiple dose (Day 8)  AUC~0--24~ (ng·h/mL)22,97420,5651.12 \[0.90, 1.39\]  *C* ~max~ (ng/mL)320125021.28 \[0.99, 1.65\]*CI* confidence interval, *AUC* ~*0--24h*~ area under the plasma concentration-time curve from time 0 to 24 h post dose, *AUC* ~*0--∞*~ area under the plasma concentration-time curve from time 0 h to infinity, *C* ~*max*~ maximum observed drug concentration in plasma^a^ *n* = 22^b^ *n* = 23Fig. 3Between-group ratios for AUC and *C* ~max~ after a single dose (Day 1) and multiple dosing (Day 8). Data are ratios of the least squares means with associated 90 % confidence intervals. AUC = AUC~0--∞~ for single dosing (Day 1) and AUC~0--24~ for multiple dosing (Day 8). The reference groups are young, male, and black. *C* ~*max*~ maximum observed drug concentration in plasma, *AUC* area under the plasma concentration-time curve, *AUC* ~*0--∞*~ area under the plasma concentration-time curve from time 0 h to infinity, AUC~0--24~ area under the plasma concentration-time curve from time 0 to 24 h post dose

An assessment of pooled data from all subjects who received AZL-M showed no difference in AZL exposure between a single dose AUC~0--∞~ (Day 1) and AUC~0--24~ at steady state after multiple dosing (Day 8) (LS mean 22281 vs. 22141 ng·h/mL, respectively; AUC~0--∞~ Day 1/AUC~0--24~ Day 8 ratio 0.99, 90 % CI 0.93, 1.06). Similarly, no notable differences between single-dose (Day 1) and multiple-dose (Day 8) pharmacokinetic parameters were evident according to age, sex, or race (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}).

Steady state plasma trough AZL concentrations (*C*~min~) on Days 6 through 8 differed less than 20 % (213.2, 249.5, and 250.6 ng/mL for Days 6, 7, and 8, respectively). No statistically significant difference was noted between *C*~min~ values on Days 7 and 8 (*p* = 0.947).

The results of subgroup analyses suggested a higher AZL *C*~max~ and AUC (56--57 % higher on Day 8) in elderly women compared with young women, although this was based on relatively small numbers of subjects (11 vs. 12, respectively) and one young black woman had substantially lower *C*~max~ and AUC values (322 ng/mL and 3059 ng·h/mL on Day 8) compared with the rest of the study population. Elderly women also had higher AZL *C*~max~ (57 % higher) and AUC~0--24~ (35 % higher) compared with elderly men, although individual *C*~max~ and AUC values for both elderly women and men overlapped.

Safety and Tolerability {#Sec11}
-----------------------

The incidence and pattern of adverse events in subjects receiving AZL-M did not appear to be influenced by age, sex, or race (Table [4](#Tab4){ref-type="table"}). The percentage of subjects reporting at least one adverse event was similar for AZL-M (32 %; 15/47 subjects) and placebo (29 %; 4/14 subjects). No subjects discontinued the study and no serious adverse events were reported. Headache was the most common adverse event (reported by four subjects \[8.5 %\] receiving AZL-M). Nausea, fatigue, blood pressure increase, dizziness, and hot flush were each experienced by two subjects (4.3 %) receiving AZL-M. Treatment-emergent adverse events that were each reported by one subject were flatulence, vomiting, injection site hemorrhage, contusion, heart rate increase, decreased appetite, muscle spasms, and muscle tightness. Two subjects had abnormal laboratory values during the study (one AZL-M subject with abnormal alanine transaminase, aspartate aminotransferase, and γ-glutamyltransferase and one placebo subject with an abnormal creatine kinase value). No subject discontinued the study because of an abnormal laboratory value, and no abnormal laboratory value was considered a serious adverse advent. There were no clinically important changes in 12-lead ECGs or physical examination findings.Table 4Adverse events reported by ≥2 subjects in any group by age, sex, and racePreferred term^a^AZL-MPlaceboAZL-MPlaceboAll subjects*N* = 47*N* = 14---- Any event15 (31.9)4 (28.6)---- Headache4 (8.5)0---- Dizziness2 (4.3)0---- Nausea2 (4.3)2 (14.3)---- Fatigue2 (4.3)0---- Hot flush2 (4.3)0---- BP increased2 (4.3)0----AgeYoungElderly*N* = 24*N* = 8*N* = 23*N* = 6 Headache3 (12.5)01 (4.3)0 Dizziness2 (8.3)000 Nausea2 (8.3)2 (25.0)00 Fatigue2 (8.3)000 Hot flush2 (8.3)000 BP increased002 (8.7)0SexMaleFemale*N* = 24*N* = 8*N* = 23*N* = 6 Headache1 (4.2)03 (13.0)0 Dizziness002 (8.7)0 Nausea1 (4.2)2 (25.0)1 (4.3)0 Fatigue2 (8.3)000 Hot flush2 (8.3)000 BP increased1 (4.2)01 (4.3)0RaceWhiteBlack*N* = 24*N* = 8*N* = 23*N* = 6 Headache3 (12.5)01 (4.3)0 Dizziness2 (8.3)000 Nausea2 (8.3)1 (12.5)01 (16.7) Fatigue2 (8.3)000 Hot flush2 (8.3)000 BP increased1 (4.2)01 (4.3)0Data are presented as *n* (%)AZL-M azilsartan medoxomil, *BP* blood pressure^a^A subject who reported ≥2 adverse events within the same preferred term was counted only once for that term

Mean blood pressure tended to decrease over the study period in subjects receiving AZL-M. Transient systolic blood pressure measurements meeting the predefined criteria of very low (\<90 mmHg) were recorded for seven subjects (15 %) on AZL-M, but hypotension was not reported as an adverse event in any subject. An overall decrease in blood pressure was expected and is consistent with the clinical benefit of the drug. Of particular relevance to the aims of the current study, there was no evidence of a relationship of age, sex, or race with very low blood pressure measurements.

Discussion {#Sec12}
==========

In this single-center, single-blind, randomized, parallel-group, single- and multiple-dose study, we investigated the impact of age, sex, and race on exposure to AZL (the active moiety of AZL-M) after administration of AZL-M 60 mg (capsule formulation) once daily. Although AZL-M has been shown to decrease blood pressure in a dose-dependent manner in a general population of subjects with mild-to-moderate hypertension \[[@CR11]--[@CR13]\], pharmacokinetic analyses such as the current study are important for determining the potential need for dosing adjustments in key subpopulations. We found that sex and race did not have any clinically relevant influence on AZL exposure. Although a small increase in AZL exposure was seen in elderly vs. young subjects, the differences (36 % higher AUC~0--∞~ \[single dose\], 26 % higher AUC~0--24~ \[multiple dose\], and 37 % higher single-dose *C*~max~) were not considered to be clinically relevant. Further subgroup analyses suggested higher AZL exposure in elderly women compared with young women, but the analysis was relatively underpowered and skewed by an outlier. Similarly, elderly women also had higher AZL exposure compared with elderly men, although there was overlap in individual values, suggesting no need for dose adjustments. These findings in subpopulations supplement other recently published pharmacokinetic data suggesting that there is also no clinically relevant effect of any degree of renal impairment (including end-stage renal disease) on AZL exposure after AZL-M administration \[[@CR7]\]. The pharmacokinetic parameter estimates in the current analysis are broadly consistent with those reported in previous studies \[[@CR2], [@CR5], [@CR7]\]. Mean elimination half-life was 10--12 h across the different subgroups and median *t*~max~ was 4.0 h after multiple dosing. We also confirmed that oral AZL-M administration displayed linear kinetics (ratio close to unity) and that the Day 8 multiple-dose measurements were carried out at steady state in the absence of any continuous AZL accumulation (no statistically significant difference between *C*~min~ values on Days 7 and 8) or any unexpected accumulation or reduction in exposure that might reflect time-dependent changes in AZL pharmacokinetics.

The ARBs are a recommended treatment option in elderly hypertensive patients, especially in those with CKD and proteinuria \[[@CR1], [@CR9], [@CR10]\]. The current study provides reassuring pharmacokinetic data for AZL-M in this vulnerable population. This class of drugs is also a recommended treatment option in black hypertensive patients, especially in those with diabetes and/or kidney disease and especially in combination with either a diuretic or a calcium channel blocker (although it has been suggested that ARBs may be less effective in black patients when used as monotherapy) \[[@CR1], [@CR14], [@CR15]\]. Preliminary results based on an analysis of three randomized controlled trials suggest that, at maximum approved doses, AZL-M lowers blood pressure more effectively in black patients with hypertension than the ARBs olmesartan or valsartan \[[@CR16]\]. The current study complements this evidence by suggesting that AZL-M can be used effectively in black patients without the need for dose adjustment.

The current study also provided the opportunity to assess the safety and tolerability of AZL-M in these subpopulations. We found that AZL-M 60 mg (capsule formulation) once daily was safe and well tolerated irrespective of age, sex, and race. It should be noted that the AZL-M capsule formulation used in the current study was switched to a once-daily tablet formulation (20, 40, or 80 mg) during later-phase clinical development. Unlike the capsule formulation, the commercially available tablet is not affected by food and provides approximately 70 % greater exposure to AZL compared with the capsule in the fasted state \[[@CR6]\].

Conclusion {#Sec13}
==========

In this study, age, sex, and race had no clinically relevant influence on exposure to AZL (the active moiety of AZL-M) during single and multiple dosing of AZL-M 60-mg capsules once daily in healthy volunteers. Similarly, age, sex, and race had no impact on AZL-M safety and tolerability. These results suggest that no AZL-M dose adjustments are required based on age, sex, or race (black or white).
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